Organon & Co. (NYSE:OGN) Shares Sold by Royal Bank of Canada

Royal Bank of Canada trimmed its holdings in shares of Organon & Co. (NYSE:OGN – Get Rating) by 16.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 345,904 shares of the company’s stock after selling 65,907 shares during the period. Royal Bank of Canada owned approximately 0.14% of Organon & Co. worth $8,095,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. CoreCap Advisors LLC acquired a new position in Organon & Co. during the 2nd quarter valued at about $27,000. Ellevest Inc. raised its holdings in Organon & Co. by 311.9% during the third quarter. Ellevest Inc. now owns 1,145 shares of the company’s stock worth $27,000 after purchasing an additional 867 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in Organon & Co. during the third quarter worth approximately $28,000. Truvestments Capital LLC acquired a new stake in Organon & Co. in the second quarter worth approximately $33,000. Finally, Coston McIsaac & Partners bought a new position in Organon & Co. during the 2nd quarter valued at $33,000. 75.74% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

OGN opened at $22.68 on Friday. The company has a market capitalization of $5.77 billion, a PE ratio of 6.32, a P/E/G ratio of 0.95 and a beta of 0.80. The stock’s fifty day moving average is $28.36 and its 200-day moving average is $27.02. Organon & Co. has a one year low of $22.50 and a one year high of $39.09.

Organon & Co. (NYSE:OGN – Get Rating) last issued its quarterly earnings results on Thursday, February 16th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.04). Organon & Co. had a negative return on equity of 118.21% and a net margin of 14.85%. The business had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the firm posted $1.37 earnings per share. Organon & Co.’s revenue was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Organon & Co. will post 4.43 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 16th. Investors of record on Monday, February 27th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 4.94%. The ex-dividend date of this dividend is Friday, February 24th. Organon & Co.’s payout ratio is 31.20%.

Organon & Co. Company Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.